209 related articles for article (PubMed ID: 11267196)
1. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.
Machado PG; Garcia C; Felipe CR; Garcia R; Franco M; Delcelo R; Silva HT; Medina JO
Transplant Proc; 2001; 33(1-2):1074-5. PubMed ID: 11267196
[No Abstract] [Full Text] [Related]
2. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
Kahan BD
Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.
Tedesco Silva H; Felipe CR; Machado PG; Garcia R; Motegi S; Hosaka BH; Hanzawa NM; Park SI; Casarini D; Lima VC; Franco M; Medina-Pestana JO
Transplant Proc; 2003 May; 35(3 Suppl):177S-180S. PubMed ID: 12742493
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
Keogh A; Richardson M; Ruygrok P; Spratt P; Galbraith A; O'Driscoll G; Macdonald P; Esmore D; Muller D; Faddy S
Circulation; 2004 Oct; 110(17):2694-700. PubMed ID: 15262845
[TBL] [Abstract][Full Text] [Related]
8. Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients.
Hricik DE
Transplant Proc; 2003 May; 35(3 Suppl):73S-78S. PubMed ID: 12742471
[TBL] [Abstract][Full Text] [Related]
9. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
Smith JM; Nemeth TL; McDonald RA
Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
[TBL] [Abstract][Full Text] [Related]
10. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
Lodge JP; Pollard SG
Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
[No Abstract] [Full Text] [Related]
11. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients.
Yoshimura N; Oka T; Ohmori Y; Yasumura T; Nakai I; Hamashima T; Nakajima H; Okamoto M; Nakamura K; Mizuta N
Transplant Proc; 1998 Feb; 30(1):33-5. PubMed ID: 9474949
[No Abstract] [Full Text] [Related]
12. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
[No Abstract] [Full Text] [Related]
13. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L
Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
[No Abstract] [Full Text] [Related]
14. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
Tsai MK; Chueh SC; Hu RH; Lee PH
J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
17. [Immunosuppression with sirolimus so donor kidneys survive longer].
MMW Fortschr Med; 2004 Aug; 146(31-32):46-7. PubMed ID: 15529711
[No Abstract] [Full Text] [Related]
18. Rapamycin in a porcine renal transplant model.
Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
[No Abstract] [Full Text] [Related]
19. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
20. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
